Adial Pharmaceuticals, Inc. (NASDAQ:ADIL – Get Free Report)’s share price passed above its 50-day moving average during trading on Wednesday. The stock has a 50-day moving average of $4.75 and traded as high as $5.15. Adial Pharmaceuticals shares last traded at $5.05, with a volume of 83,319 shares traded.
Analyst Ratings Changes
A number of equities research analysts have recently issued reports on ADIL shares. Alliance Global Partners started coverage on shares of Adial Pharmaceuticals in a report on Monday, August 3rd. They set a “buy” rating and a $11.00 price target on the stock. Wall Street Zen raised shares of Adial Pharmaceuticals to a “sell” rating in a research note on Saturday, August 15th. Finally, Weiss Ratings downgraded shares of Adial Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Monday, October 12th. Two research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $8.33.
View Our Latest Stock Analysis on Adial Pharmaceuticals
Adial Pharmaceuticals Stock Performance
The firm has a 50 day moving average of $4.75 and a 200-day moving average of $3.28. The stock has a market capitalization of $13.28 million, a PE ratio of -0.34 and a beta of 1.50.
Adial Pharmaceuticals (NASDAQ:ADIL – Get Free Report) last released its earnings results on Friday, August 14th. The company reported ($11.25) earnings per share for the quarter, missing the consensus estimate of ($1.03) by ($10.22).
About Adial Pharmaceuticals
Adial Pharmaceuticals, Inc is a clinical-stage biotechnology company focused on developing therapeutics for addiction and related disorders. The company’s primary product candidate is AD04, an investigational formulation of ondansetron, a serotonin 5-HT3 receptor antagonist, being developed as a pharmacogenetically targeted treatment for alcohol use disorder.
AD04 is designed for people with alcohol use disorder who have specific genetic characteristics that may influence treatment response.
Recommended Stories
- Five stocks we like better than Adial Pharmaceuticals
- Boeing Got Its MAX 10 Approval, But Q3 Delivered a Reality Check
- The Invisible AI Backbone: Corning’s AI Fiber Play
- Heavy Metal: Why Nucor Could Be an Overlooked AI Infrastructure Winner
- Why Tesla’s Upside Is About More Than a SpaceX Merger
Receive News & Ratings for Adial Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adial Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
